Saved in:
Bibliographic Details
Main Authors: Ji, Rui, Wu, Jiasha, Wang, Luyi, Xu, Fusheng, Hu, Jiwen, Shi, Yejiao, Liu, Siyao, Xu, Feng, Hu, Xiaochun, Hu, Honggang
Format: Artículo científico
Language:en
Published: Advanced healthcare materials 2026
Subjects:
Online Access:https://pubmed.ncbi.nlm.nih.gov/41311326/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1868266119893090305
author Ji, Rui
Wu, Jiasha
Wang, Luyi
Xu, Fusheng
Hu, Jiwen
Shi, Yejiao
Liu, Siyao
Xu, Feng
Hu, Xiaochun
Hu, Honggang
author_facet Ji, Rui
Wu, Jiasha
Wang, Luyi
Xu, Fusheng
Hu, Jiwen
Shi, Yejiao
Liu, Siyao
Xu, Feng
Hu, Xiaochun
Hu, Honggang
Ji, Rui
Wu, Jiasha
Wang, Luyi
Xu, Fusheng
Hu, Jiwen
Shi, Yejiao
Liu, Siyao
Xu, Feng
Hu, Xiaochun
Hu, Honggang
collection PubMed - marine biology
contents Targeted GPX4 Degradation Mediated by Hypoxia-Overcoming Nano-PDTACs for Synergistic Ferroptosis-Immunotherapy. Ji, Rui Wu, Jiasha Wang, Luyi Xu, Fusheng Hu, Jiwen Shi, Yejiao Liu, Siyao Xu, Feng Hu, Xiaochun Hu, Honggang Ferroptosis Humans Photochemotherapy Immunotherapy Phospholipid Hydroperoxide Glutathione Peroxidase Cell Line, Tumor Animals Female Mice Triple Negative Breast Neoplasms Platinum Photosensitizing Agents Nanoparticles For triple-negative breast cancer (TNBC), ferroptosis is a promising therapeutic strategy, with photodynamic therapy (PDT) being an effective method to induce it. However, PDT-induced ferroptosis has limitations such as poor tumor targeting, unclear target specificity, and hypoxia. Thus, we developed a novel nano-photodegradation-targeting chimera (Nano-PDTAC) that achieves efficient ferroptosis in TNBC cells. The Nano-PDTAC (PCN@Pt-TR) is constructed by attaching a GPX4-targeting peptide (T) and a tumor-targeting peptide (R) to platinum nanozyme-modified iron-porphyrin frameworks (PCN@Pt). PCN@Pt-TR enhances tumor targeting by binding to the αvβ3 integrin receptor on tumor cell surfaces, and it has potential for magnetic resonance imaging (MRI)-guided therapy. Once inside tumor cells, PCN@Pt-TR efficiently induces ferroptosis by targeting and degrading the GPX4 protein. Crucially, the O produced by the Pt nanozyme continuously replenished, sustaining the degradation. Additionally, tumor cells undergoing ferroptosis mediated by Nano-PDTAC can induce immunogenic cell death (ICD), and enhance the effectiveness of immune checkpoint blockade. Thus, this is a valuable approach for inducing ferroptosis based on GPX4-targeted Nano-PDTAC, which can overcome the many issues associated with traditional photosensitizers in ferroptosis and may advance the application of ferroptosis in tumor immunotherapy.
format Artículo científico
id pubmed_41311326
institution PubMed
language en
publishDate 2026
publisher Advanced healthcare materials
record_format pubmed
spellingShingle Targeted GPX4 Degradation Mediated by Hypoxia-Overcoming Nano-PDTACs for Synergistic Ferroptosis-Immunotherapy.
Ji, Rui
Wu, Jiasha
Wang, Luyi
Xu, Fusheng
Hu, Jiwen
Shi, Yejiao
Liu, Siyao
Xu, Feng
Hu, Xiaochun
Hu, Honggang
Ferroptosis
Humans
Photochemotherapy
Immunotherapy
Phospholipid Hydroperoxide Glutathione Peroxidase
Cell Line, Tumor
Animals
Female
Mice
Triple Negative Breast Neoplasms
Platinum
Photosensitizing Agents
Nanoparticles
Targeted GPX4 Degradation Mediated by Hypoxia-Overcoming Nano-PDTACs for Synergistic Ferroptosis-Immunotherapy. Ji, Rui Wu, Jiasha Wang, Luyi Xu, Fusheng Hu, Jiwen Shi, Yejiao Liu, Siyao Xu, Feng Hu, Xiaochun Hu, Honggang Ferroptosis Humans Photochemotherapy Immunotherapy Phospholipid Hydroperoxide Glutathione Peroxidase Cell Line, Tumor Animals Female Mice Triple Negative Breast Neoplasms Platinum Photosensitizing Agents Nanoparticles For triple-negative breast cancer (TNBC), ferroptosis is a promising therapeutic strategy, with photodynamic therapy (PDT) being an effective method to induce it. However, PDT-induced ferroptosis has limitations such as poor tumor targeting, unclear target specificity, and hypoxia. Thus, we developed a novel nano-photodegradation-targeting chimera (Nano-PDTAC) that achieves efficient ferroptosis in TNBC cells. The Nano-PDTAC (PCN@Pt-TR) is constructed by attaching a GPX4-targeting peptide (T) and a tumor-targeting peptide (R) to platinum nanozyme-modified iron-porphyrin frameworks (PCN@Pt). PCN@Pt-TR enhances tumor targeting by binding to the αvβ3 integrin receptor on tumor cell surfaces, and it has potential for magnetic resonance imaging (MRI)-guided therapy. Once inside tumor cells, PCN@Pt-TR efficiently induces ferroptosis by targeting and degrading the GPX4 protein. Crucially, the O produced by the Pt nanozyme continuously replenished, sustaining the degradation. Additionally, tumor cells undergoing ferroptosis mediated by Nano-PDTAC can induce immunogenic cell death (ICD), and enhance the effectiveness of immune checkpoint blockade. Thus, this is a valuable approach for inducing ferroptosis based on GPX4-targeted Nano-PDTAC, which can overcome the many issues associated with traditional photosensitizers in ferroptosis and may advance the application of ferroptosis in tumor immunotherapy.
title Targeted GPX4 Degradation Mediated by Hypoxia-Overcoming Nano-PDTACs for Synergistic Ferroptosis-Immunotherapy.
topic Ferroptosis
Humans
Photochemotherapy
Immunotherapy
Phospholipid Hydroperoxide Glutathione Peroxidase
Cell Line, Tumor
Animals
Female
Mice
Triple Negative Breast Neoplasms
Platinum
Photosensitizing Agents
Nanoparticles
url https://pubmed.ncbi.nlm.nih.gov/41311326/